MSLN mesothelin
ENSG00000102854 · protein coding · Open Targets profile
Membrane-anchored forms may play a role in cellular adhesion.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Antibody
- Advanced Clinical, GO CC high conf, UniProt loc med conf, UniProt SigP or TMHMM, Human Protein Atlas loc
- PROTAC
- Database Ubiquitination
- Other modalities
- Advanced Clinical
gnomAD loss of function constraint: o/e 1.1295000314712524 (upper bound 1.357200026512146). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 6 registry trials, updated in the last three years, of the most advanced drugs against MSLN (anetumab ravtansine, LMB-100, amatuximab), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Aaron S MansfieldDana-Farber - Harvard Cancer Center LAO · 1 of 1 trials Phase 2+
- Azam GhafoorNational Cancer Institute (NCI) · 1 of 1 trials Phase 2+
- Stephanie LheureuxUniversity Health Network Princess Margaret Cancer Center LAO · 1 of 1 trials Phase 2+
- Anna SpreaficoUniversity Health Network Princess Margaret Cancer Center LAO · 0 of 1 trials Phase 2+
- David S SchrumpNational Cancer Institute (NCI) · 0 of 1 trials Phase 2+
- Raffit HassanNational Cancer Institute (NCI) · 0 of 1 trials Phase 2+
Registry trials of anetumab ravtansine, LMB-100, amatuximab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 3 of 6 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. Source: ClinicalTrials.gov, fetched live.
11 trials of drugs against MSLN were stopped early; 1 give no reason
Terminated, withdrawn and suspended interventional trials of anetumab ravtansine, LMB-100, amatuximab, SS1(DSFV)-PE38, RG-7600, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 11 most recent of 11.
- terminated · 2024-04-16 · National Cancer Institute (NCI) · LMB-100“Study was terminated due to slow accrual.”
- terminated · 2024-02-02 · National Cancer Institute (NCI) · LMB-100“Study was closed early due to slow accrual.”
- withdrawn · 2024-02-02 · National Cancer Institute (NCI) · LMB-100“No participants enrolled.”
- terminated · 2023-08-04 · Bayer · BAY94-9343 (Anetumab ravtansine)“Due to strategic company decisions, the development of anetumab ravtansine was stopped.”
- terminated · 2023-01-06 · Mayo Clinic · Anetumab Ravtansine“slow accrual”
- terminated · 2021-12-02 · National Cancer Institute (NCI) · LMB-100“Due to the Food and Drug Administration's recent approval of Nivolumab plus Ipilimumab as first line treatment for Mesothelioma, the principal investigator decided to end the study early (prior to reaching enrollment goal).”
- terminated · 2020-03-17 · Morphotek · Amatuximab“Due to business reasons”
- terminated · 2019-12-17 · National Cancer Institute (NCI) · Amatuximab (MORab-009)No reason given
- terminated · 2019-11-22 · National Cancer Institute (NCI) · LMB-100“Due to fatal occurrence (pneumonitis) attributed to one of the study drugs.”
- terminated · 2019-05-21 · National Cancer Institute (NCI) · Anetumab Ravtansine“Due to slow, insufficient accrual.”
- terminated · 2016-07-26 · Hoffmann-La Roche · matched by the registry's drug synonyms“The study was prematurely terminated because the emerging benefit:risk ratio did not justify continuing dosing patients.”
Paediatric incentives and obligations for MSLN's drugs
For anetumab ravtansine, LMB-100, amatuximab, SS1(DSFV)-PE38, RG-7600: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: yes · MSLN is on the list. Membership alone neither requires nor waives a pediatric study.Rule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names anetumab ravtansine, lmb-100, amatuximab, ss1(dsfv)-pe38, rg-7600Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/13/1222 withdrawn 16 Jan 2014: Treatment of malignant mesothelioma; EU/3/18/2084 withdrawn 19 Nov 2018: Treatment of ovarian cancer; EU/3/12/1073 withdrawn 6 Dec 2012: Treatment of malignant mesotheliomaRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: no · EMA lists no centrally authorised medicine of anetumab ravtansine, lmb-100, amatuximab, ss1(dsfv)-pe38, rg-7600Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of anetumab ravtansine, lmb-100, amatuximab, ss1(dsfv)-pe38, rg-7600Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: no · No interventional study of anetumab ravtansine, lmb-100, amatuximab, ss1(dsfv)-pe38, rg-7600 includes patients under 18Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 5 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.